NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 358 filers reported holding NOVOCURE LTD in Q4 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $420,800 | -18.0% | 6,997 | 0.0% | 0.01% | -25.0% |
| Q4 2022 | $513,230 | -99.9% | 6,997 | 0.0% | 0.01% | 0.0% |
| Q3 2022 | $531,632,000 | +9.3% | 6,997 | 0.0% | 0.01% | +33.3% |
| Q2 2022 | $486,292,000 | -16.1% | 6,997 | 0.0% | 0.01% | -14.3% |
| Q1 2022 | $579,701,000 | +10.3% | 6,997 | 0.0% | 0.01% | +40.0% |
| Q4 2021 | $525,335,000 | -35.4% | 6,997 | 0.0% | 0.01% | -44.4% |
| Q3 2021 | $812,841,000 | -47.6% | 6,997 | 0.0% | 0.01% | -43.8% |
| Q2 2021 | $1,552,075,000 | +28.2% | 6,997 | 0.0% | 0.02% | +14.3% |
| Q4 2020 | $1,210,761,000 | – | 6,997 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |